One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
ORIC Pharmaceuticals, Inc.
ORIC · NMS · Healthcare · Biotechnology
Current price
$11.99
52-week range
$7.23 - $14.68
Market cap
$1.24B
Balance sheet
Healthy
-54.07x Concerning
Net cash $258.76M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -39.8% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 1.6% (peer median: 9.3%).
What this company does
ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a company trying to create new medicines for cancer, specifically looking for ways to fight cancer that has become resistant to existing treatments. Their main focus is on developing two experimental drugs, one for certain types of lung cancer and another for prostate cancer, which are currently in early testing stages. This matters because if these drugs prove successful, they could offer new hope for patients with these difficult-to-treat cancers.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-29.21M
FY2024 Q4
$-28.27M
FY2025 Q1
$-32.92M
FY2025 Q2
$-30.91M
FY2025 Q3
$-25.15M
FY2025 Q4
$-22.71M
FY2026 Q1
$-32.44M
FY2026 Q2
$-31.96M
Revenue
—
Net income
$-41.49M
Diluted EPS
-0.38
Operating cash flow
$-31.61M
Free cash flow
$-31.96M
Fetching…
Sources
Revenue
—
Net income
$-35.77M
Diluted EPS
-0.34
Operating cash flow
$-32.44M
Free cash flow
$-32.44M
Fetching…
Sources
Revenue
—
Net income
$-30.50M
Diluted EPS
-0.25
Operating cash flow
$-22.48M
Free cash flow
$-22.71M
Fetching…
Sources
Revenue
—
Net income
$-32.59M
Diluted EPS
-0.33
Operating cash flow
$-25.11M
Free cash flow
$-25.15M
Fetching…
Sources
Revenue
—
Net income
$-36.35M
Diluted EPS
-0.47
Operating cash flow
$-30.84M
Free cash flow
$-30.91M
Fetching…
Sources
Revenue
—
Net income
$-30.02M
Diluted EPS
-0.42
Operating cash flow
$-32.53M
Free cash flow
$-32.92M
Fetching…
Sources
Revenue
—
Net income
$-36.31M
Diluted EPS
-0.52
Operating cash flow
$-28.05M
Free cash flow
$-28.27M
Fetching…
Sources
Revenue
—
Net income
$-34.57M
Diluted EPS
-0.49
Operating cash flow
$-28.80M
Free cash flow
$-29.21M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $11.99
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $258.8M - more cash than debt. Interest coverage -54.1x.
Net debt
$-258.76M
Interest coverage
-54.07x
ORIC Pharmaceuticals, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ORIC
BASELINE
ORIC Pharmaceuticals, Inc.
Total debt $6.00M Interest coverage -54.07x This is the baseline the peer rows are being compared against.
Total debt $15.15M Interest coverage -121.87x Neither company has much profit cushion over interest right now.
Total debt $119.47M Interest coverage -1.04x Neither company has much profit cushion over interest right now.
Total debt $17.11M Interest coverage -14.78x Neither company has much profit cushion over interest right now.
Total debt $2.88M Interest coverage -63.33x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ORIC
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -39.8% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 1.6% (peer median: 9.3%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-7.17x
P/B
3.26x
P/S
—
EV/EBITDA
-6.35x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-39.8%
ROA
-26.0%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
13.19x
Quick ratio
12.76x
Total debt
$6.00M
Total cash
$264.76M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.32
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-111.64M
Free CF TTM
$-111.68M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—